Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
How to Play Moderna Stock After the Recent Sales Guidance Cut
12:10pm, Friday, 17'th Jan 2025
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
03:15am, Friday, 17'th Jan 2025
Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?
02:47pm, Thursday, 16'th Jan 2025
Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (MRNA -2.72%). The company, which was a leader in developing one of the initial
CDC upgrades its advisory on bird flu. Will Moderna's stock get a boost?
02:45pm, Thursday, 16'th Jan 2025
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or bird.
Is Moderna a Bad-News Buy for 2025?
08:10am, Thursday, 16'th Jan 2025
Moderna (MRNA 0.90%) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it. This helped
Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?
04:58am, Thursday, 16'th Jan 2025
Moderna (MRNA 0.90%) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but the gains didn't last long.
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
04:52am, Wednesday, 15'th Jan 2025
A bad seven-month stretch just got worse for Moderna (MRNA -1.96%). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
06:56pm, Tuesday, 14'th Jan 2025
The latest trading day saw Moderna (MRNA) settling at $34.45, representing a -1.98% change from its previous close.
Moderna Stock Plummets 17% on 2025 Sales Guidance Slash
11:30am, Tuesday, 14'th Jan 2025
The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.
ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo
09:27am, Tuesday, 14'th Jan 2025
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company
Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook
11:15pm, Monday, 13'th Jan 2025
Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
S&P 500 Gains and Losses Today: Moderna Plunges After Big Cut to Sales Forecast
05:10pm, Monday, 13'th Jan 2025
Major U.S. equities indexes were mixed to start a new trading week ahead of inflation data that could provide some clarity on the interest-rate outlook for 2025. Earnings reports from the largest U.S.
Moderna slashes 2025 sales forecast, shares sink
02:04pm, Monday, 13'th Jan 2025
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plunged almost 20% after the drugmaker pre-announced fiscal 2024 sales below expectations. The company expects sales of $3 billion to $3.1 billion, below the
S&P 500, Nasdaq slip as key tech stocks fall; US Steel shares jump, Moderna stock tanks
01:16pm, Monday, 13'th Jan 2025
US stocks saw a decline on Monday as investors continued to unload key tech shares that have been driving the bull market. The S&P 500 fell by 0.2%, while the Nasdaq Composite dropped 0.8%.
